AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00275145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Lifting weights 3 times per week; 8 different exercise each time; for each exercise, do three sets = lifting an appropriate weight between 8-12 for each set; rest 45 seconds (at least) between sets
Study NCT00275145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Exercise at 75% of maximal capacity for approximately 2 hours per week
Study NCT00275145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combo
Description: Lift weights (as described in RT group) and do aerobic exercise (as described in Aerobic group
Study NCT00275145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continued Sedentary lifestyle
Description: No changes
Study NCT04233502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing
Study NCT04233502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo melatonin
Study NCT01552148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: USguided bilateral TAP block
Description: 23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
Study NCT01552148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Patient Controlled Analgesia
Description: Morphine PCA i.v. (bolus 2mg, lockout 8 min)
Study NCT00125853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 2.5mg daily
Study NCT00125853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol 25mg daily
Study NCT04578899 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transvertebral magnetic stimulation
Description: Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15
Study NCT04578899 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transvertebral magnetic stimulation
Description: Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15
Study NCT00548002 — intervention group
Intervention type: DRUG
Intervention: trovafloxacin and levofloxacin
Description: Trovafloxacin: \<60 kg 200 mg iv/orally once daily and >60 kg 300 mg iv/orally once daily Levofloxacin: \< 60 kg 500 mg iv/orally once daily and >60 kg 500 mg iv/orally bid
Study NCT02032264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Chromosome Screening
Description: On day 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS), will be performed via next generation sequencing and results will be available at the time of study completion.
Study NCT02032264 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Morphologically Best
Description: Patients in this arm of the study will not receive CCS in selection of their embryo for transfer. The best looking embryo (morphology) will be transferred
Study NCT02831998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep
Description: Apply topically.
Study NCT02831998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically.
Study NCT02831998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZP Vehicle
Description: Apply topically.
Study NCT00574600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAAVI DNA-C2 vaccine
Description: DNA vaccine
Study NCT00574600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAAVI MVA-C vaccine
Description: Boost vaccine
Study NCT00574600 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccine
Study NCT03168698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
Study NCT03168698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
Study NCT06104579 — intervention group
Intervention type: OTHER
Intervention: Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection
Description: Concordance between the two registers was analysed using Cohen´s Kappa.
Study NCT01741311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3H+ (Holistic Health for HIV)
Description: Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
Study NCT01741311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HHRP+ (Holistic Health Recovery Program)
Description: 12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
Study NCT02965053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS789
Study NCT02965053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02965053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renvela
Study NCT02143063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: prize contingency management on a traditional twice weekly schedule for cocaine abstinence
Study NCT02143063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prize contingency management on a variable interval schedule for cocaine abstinence
Study NCT02143063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Study NCT02143063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard care
Study NCT03841006 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: dynamic MRI pelvis
Study NCT00576823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: Dose: 0.2 mg/kg/day~Route: oral
Study NCT04470570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-Education
Description: 1) Cross-Education: The effect that exercising the uninvolved upper extremity will have a positive effect on the involved upper extremity.
Study NCT04470570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood-Flow Restriction Training
Description: 1) Blood Flow Restriction: A type of resistance training using a blood-pressure like cuff that partially occludes venous blood flow to induce various neurohormonal effects and allows strength gains to be achieved at very low loads of resistance.
Study NCT00123019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and diet
Description: Advice and measurement only
Study NCT00123019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet, Weight Reducing
Description: Measurement, advice, environmental and behavioral group interventions
Study NCT00123019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Level 1
Description: Annual assessment of weight and waist circumference, questionnaire on work, health issues, advice on diet, physical activity and other health issues.
Study NCT00123019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Level 2
Description: All Level 1 activities plus ongoing environmental interventions in worksite and weight management groups in worksite over a 24 month period.
Study NCT04741854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) Therapy
Description: PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
Study NCT03688997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulator training
Description: bench-top simulator with computer acquired assessments, designed to allow novices to acquire basic surgical skills in knot tying. The simulator measures the forces used and applied on the tissue while ligating a vessel. Simulator training was included in both arms (expert and novice groups).
Study NCT01654835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low blood pressure alert
Description: A Low Blood Pressure condition as specified (SAP \<80 mmHg)will trigger an page to be sent to all anesthesia providers in \<1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support.
Study NCT01654835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: A Low Blood Pressure condition as specified (SAP \<80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
Study NCT01849679 — intervention group
Intervention type: OTHER
Intervention: Evaluation of Swallowing
Description: Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
Study NCT03334695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Description: Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp in single-use vials.
Study NCT03334695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as sterile 0.9% saline for injection.
Study NCT04851171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Ureteroscopy
Description: Flexible ureteroscopy is the use of flexible ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
Study NCT04851171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Semi-rigid Ureteroscopy
Description: Semi-rigid ureteroscopy is the use of the semi-rigid ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
Study NCT00806299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide / Red Grapefruit Juice
Description: Fixed sequence of loperamide 4 mg with and without red grapefruit juice
Study NCT00806299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide/ White Grapefruit Juice
Description: Fixed sequence of loperamide 4 mg with and without white grapefruit juice
Study NCT00806299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide / Pink Grapefruit Juice
Description: Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
Study NCT03166397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
Study NCT03166397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
Study NCT03166397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL
Description: TIL administration
Study NCT03166397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.
Study NCT01552148 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine Patient Controlled Analgesia
Description: Morphine PCA i.v. (bolus 2mg, lockout 8min)
Study NCT02980510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil
Study NCT02980510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan
Study NCT02430103 — intervention group
Intervention type: DRUG
Intervention: Goserelin 3.6 MG
Description: In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.
Study NCT02909881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Use of PhytoSpherix at 0 g/min
Description: PhytoSpherix (Sweet-corn derived sugar) will be fed at 0 g/min during a 150 min cycling exercise
Study NCT02909881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Use of PhytoSpherix at 1 g/min
Description: PhytoSpherix (Sweet-corn derived sugar) will be fed at 1 g/min during a 150 min cycling exercise
Study NCT02909881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Use of PhytoSpherix at 1.5 g/min
Description: PhytoSpherix (Sweet-corn derived sugar) will be fed at 1.5 g/min during a 150 min cycling exercise
Study NCT03166397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg fixed dose
Study NCT03166397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg up to 100 mg
Study NCT03166397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT Protocol
Description: FMT given both directly into the colon via colonoscopy and orally using capsules (12 capsules each time).~FMT will be taken from melanoma patients treated with Anti PD-1 who achieved a durable response of more than 12 months.
Study NCT02909881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Use of PhytoSpherix at 2 g/min
Description: PhytoSpherix (Sweet-corn derived sugar) will be fed at 2 g/min during a 150 min cycling exercise
Study NCT02909881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Description: Male endurance athletes will complete a cycling exercise for 150 min at 50% of their respective maximum wattage
Study NCT01550016 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Clinical follow-up and laboratory investigations.
Study NCT02787733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrus flavonoid
Description: Daily dose of 500mg divided over two capsules
Study NCT01990911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.
Study NCT01990911 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Medical therapy
Description: Subjects will continue on their standard medical therapy as prescribed by their treating physician
Study NCT01990911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical therapy
Description: Subjects will continue on their standard medical therapy as prescribed by their treating physician
Study NCT02900222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic choroid plexus coagulation
Description: A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.
Study NCT01406808 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: genetic risk score for coronary risk factors
Description: genetic risk score based on coronary artery disease genetic risk variants (SNPs)
Study NCT02852811 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group education
Description: Intervention involving two education session with topics common in menopause transition.
Study NCT00308919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST09
Description: Treatment with WST09 Vascular Photodynamic therapy
Study NCT03447977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical
Description: cervical spine manual therapy
Study NCT03447977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic
Description: thoracic spine manual therapy
Study NCT03447977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: exercises for pain
Study NCT02456675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB040093 Monotherapy
Description: INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
Study NCT02456675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB040093
Description: INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
Study NCT02456675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Description: The dose of itacitinib will be given orally once daily (QD).
Study NCT00296023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT00296023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00296023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Study NCT00296023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study NCT00296023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00296023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00296023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT00296023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Study NCT00296023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00857298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be \~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
Study NCT01828385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate + rocuronium + sugammadex
Study NCT01828385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline + rocuronium + sugammadex
Study NCT03179059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test at Baseline
Description: Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
Study NCT03179059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test at follow up survey
Description: We will provide a free pregnancy tests in for the future use, they are randomly selected from intervention #1 treatment group.
Study NCT00631397 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound machine
Description: Weekly Bone Density measurements using the Sonometer
Study NCT03937232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cross-Education
Description: Home exercise program + usual care
Study NCT03937232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Visual Feedback
Description: Home exercise program + usual care
Study NCT03937232 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Visual Feedback
Description: Home exercise program + usual care
Study NCT03937232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting
Study NCT03937232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting
Study NCT02731456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: altitude exposure
Description: altitude exposure
Study NCT04218552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD209
Description: PO, Once daily(QD), 8weeks
Study NCT02787733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of 500mg divided over two capsules
Study NCT01058902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg
Description: Aspirin 75 mg
Study NCT01058902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75 mg
Description: Aspirin 75 mg